X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs BIOCON LTD - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA BIOCON LTD ABBOTT INDIA/
BIOCON LTD
 
P/E (TTM) x 36.7 50.6 72.4% View Chart
P/BV x 9.4 7.4 127.9% View Chart
Dividend Yield % 0.7 0.2 466.2%  

Financials

 ABBOTT INDIA   BIOCON LTD
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
BIOCON LTD
Mar-18
ABBOTT INDIA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs6,1101,188 514.3%   
Low Rs3,996305 1,310.2%   
Sales per share (Unadj.) Rs1,552.268.7 2,258.7%  
Earnings per share (Unadj.) Rs188.87.6 2,500.2%  
Cash flow per share (Unadj.) Rs196.414.0 1,406.0%  
Dividends per share (Unadj.) Rs55.001.00 5,500.0%  
Dividend yield (eoy) %1.10.1 812.5%  
Book value per share (Unadj.) Rs796.686.3 922.6%  
Shares outstanding (eoy) m21.25600.00 3.5%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.310.9 30.0%   
Avg P/E ratio x26.898.9 27.1%  
P/CF ratio (eoy) x25.753.4 48.1%  
Price / Book Value ratio x6.38.6 73.4%  
Dividend payout %29.113.2 220.0%   
Avg Mkt Cap Rs m107,376447,900 24.0%   
No. of employees `0003.36.1 54.0%   
Total wages/salary Rs m3,9379,311 42.3%   
Avg. sales/employee Rs Th9,929.36,705.8 148.1%   
Avg. wages/employee Rs Th1,185.11,514.2 78.3%   
Avg. net profit/employee Rs Th1,207.7736.9 163.9%   
INCOME DATA
Net Sales Rs m32,98541,234 80.0%  
Other income Rs m1,1702,062 56.7%   
Total revenues Rs m34,15543,296 78.9%   
Gross profit Rs m5,2458,291 63.3%  
Depreciation Rs m1623,851 4.2%   
Interest Rs m38615 6.2%   
Profit before tax Rs m6,2155,887 105.6%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2031,569 140.4%   
Profit after tax Rs m4,0124,531 88.5%  
Gross profit margin %15.920.1 79.1%  
Effective tax rate %35.426.7 133.0%   
Net profit margin %12.211.0 110.7%  
BALANCE SHEET DATA
Current assets Rs m22,65541,486 54.6%   
Current liabilities Rs m6,68121,413 31.2%   
Net working cap to sales %48.448.7 99.5%  
Current ratio x3.41.9 175.0%  
Inventory Days Days6564 101.3%  
Debtors Days Days2994 31.0%  
Net fixed assets Rs m83550,661 1.6%   
Share capital Rs m2133,000 7.1%   
"Free" reserves Rs m16,71548,808 34.2%   
Net worth Rs m16,92851,808 32.7%   
Long term debt Rs m017,898 0.0%   
Total assets Rs m24,16299,897 24.2%  
Interest coverage x163.710.6 1,548.3%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.40.4 330.7%   
Return on assets %16.85.2 325.4%  
Return on equity %23.78.7 271.0%  
Return on capital %36.99.6 383.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36912,058 3.1%   
Fx outflow Rs m3,8077,348 51.8%   
Net fx Rs m-3,4384,710 -73.0%   
CASH FLOW
From Operations Rs m1,5276,621 23.1%  
From Investments Rs m-2,148-6,840 31.4%  
From Financial Activity Rs m-1,024-2,397 42.7%  
Net Cashflow Rs m-1,646-2,612 63.0%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 7.9 8.4 94.0%  
FIIs % 0.1 10.7 0.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 19.9 85.9%  
Shareholders   18,270 109,995 16.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  SANOFI INDIA  DR. DATSONS LABS  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Dec 12, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS